News | Brachytherapy Systems | August 14, 2019

Brachytherapy solution shown effective for brain, prostate, and head and neck cancers

Efficacy of Isoray's Cesium Blu Showcased in Recent Studies

August 14, 2019 — Isoray announced a trio of studies recently reported at scientific meetings and published in medical journals that the company says illustrate the clinical utility of its Cesium Blu (formerly known as Cesium-131) treatment in radiation therapy applications. The company said the results will help grow market awareness of the range of clinical applications.

Among the recent studies are the findings of David Brachman, M.D., of the Barrow Neuroscience Institute on the impact of Cesium Blu-driven treatment on three types of recurrent brain cancers. According to the publication, Surgically Targeted Radiation Therapy: Safety Profile of Collagen Tile Brachytherapy in 79 Recurrent, Previously Irradiated Intracranial Neoplasms on a Prospective Clinical Trial, Cesium-powered GammaTile therapy offers recurrent brain cancer patients a safe and effective treatment.1 The findings involve patients suffering from high-grade gliomas, meningiomas and brain metastases. The results are important because recurrence of these hard-to-treat brain cancers has left patients with very limited options due to their prior radiation treatments. U.S. Food and Drug Administration (FDA)-cleared in July 2018, GammaTile therapy offers promising treatment for patients with these brain cancers.

Watch the VIDEO: Advancements in Radiation Therapy for Brain Cancer

Another recent study, Long Term Results from a Prospective Randomized Trial of 131Cs vs 125I Permanent Prostate Brachytherapy, was published by Manuj Agarwal, M.D., of the University of Maryland and Brian Moran, M.D., of the Chicago Prostate Cancer Center. It reported long-term follow-up data collected on Cesium-131 as compared to Iodine-125, a long-established prostate brachytherapy isotope. This long-term data with nine-year median follow-up shows comparable long-term biochemical control (prostate-specific antigen recurrence) results between Cesium-131 and Iodine-125 in these patients. The data supports Cesium-131 as an effective long-term solution for these patients and supports Cesium-131 as an optimal choice for prostate cancer patients. 

The impact of Cesium-131 on recurring skull base (deep neck) cancers is the focus of a case report in the Journal of Neurological Surgery Reports by Corey Savard, M.D., of Thomas Jefferson University Hospital. The joint effort of otolaryngology, radiation oncology and neurosurgical physicians is entitled, Cesium-131 Interstitial Brachytherapy for Recurrent Malignancies of the Skull Base. Presented were two cases of the especially challenging cancers that recur in a very difficult area to treat. The authors stated that the characteristics of Cesium-131 that make it effective in treating other cancers might also make it effective in treating difficult recurring skull base malignancies. Although this is a small study and the results are early, as of the published date there were no recurrences or complications noted in either case. 

For more information: www.isoray.com

References

1. Brachman D., Youssef E., Dardis C., et al. Surgically Targeted Radiation Therapy: Safety Profile of Collagen Tile Brachytherapy in 79 Recurrent, Previously Irradiated Intracranial Neoplasms on a Prospective Clinical Trial. Brachytherapy: An International Multidisciplinary Journal, May-June 2019. DOI: https://doi.org/10.1016/j.brachy.2019.04.076

2. Agarwal M., Braccioforte M.H., Amin N., et al. Long Term Results from a Prospective Randomized Trial of 131Cs vs 125I Permanent Prostate Brachytherapy. Brachytherapy: An International Multidisciplinary Journal, May-June 2019. DOI: https://doi.org/10.1016/j.brachy.2019.04.037

3. Savard C., Epps G., Bar Ad V., et al. Cesium-131 Interstitial Brachytherapy for Recurrent Malignancies of Skull Base. Journal of Neurological Surgery Reports, published online April 9, 2019. DOI: 10.1055/s-0039-1687848

Related Content

News | Coronavirus (COVID-19)

November 24, 2021 — Significant decreases in CT imaging for cancer persisted even after the peak of the COVID-19 ...

Time November 24, 2021
arrow
Videos | Radiation Therapy

Jeffrey T. Chapman, a medical student at the University of Texas Southwestern Medical Center, Explains how watching ...

Time November 24, 2021
arrow
News | Magnetic Resonance Imaging (MRI)

November 23, 2021 — Researchers at Yale University analyzing specialized MRI exams found significant changes in the ...

Time November 23, 2021
arrow
News | Interventional Radiology

November 23, 2021 — A minimally invasive ablation procedure offers long-term relief for patients who experience chronic ...

Time November 23, 2021
arrow
News | Nuclear Imaging

November 22, 2021 — IBA, a leader in particle accelerator technology, and NorthStar Medical Radioisotopes LLC, a global ...

Time November 22, 2021
arrow
News | Magnetic Resonance Imaging (MRI)

November 22, 2021 — Adolescents and young adults with post-concussive symptoms who suffered three to five concussions ...

Time November 22, 2021
arrow
News | Lung Imaging

November 19, 2021 — Lung cancer screening is recommended only for those who are at high risk for the disease — adults ...

Time November 19, 2021
arrow
News | Artificial Intelligence

November 18, 2021 — Worldwide the most common cause of cancer mortality in 2020 was lung cancer, with an estimated 1.80 ...

Time November 18, 2021
arrow
News | Artificial Intelligence

November 18, 2021 — VIDA Diagnostics Inc. (VIDA) is further removing friction in respiratory clinical trials with the ...

Time November 18, 2021
arrow
Videos | Radiopharmaceuticals and Tracers

Ana Kiess, M.D., Ph.D., assistant professor of radiation oncology and molecular radiation sciences, Johns Hopkins ...

Time November 17, 2021
arrow
Subscribe Now